TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity

被引:0
|
作者
Yimeng Ren
Yun Qian
Luoyan Ai
Yile Xie
Yaqi Gao
Ziyan Zhuang
Jinxian Chen
Ying-Xuan Chen
Jing-Yuan Fang
机构
[1] Renji Hospital,State Key Laboratory for Oncogenes and Related Genes; Division of Gastroenterology and Hepatology
[2] School of Medicine,Department of Medical Oncology
[3] Shanghai Jiao Tong University,Division of Gastrointestinal Surgery
[4] Zhongshan Hospital,undefined
[5] Fudan University,undefined
[6] Renji Hospital,undefined
[7] School of Medicine,undefined
[8] Shanghai Jiao Tong University,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Tumor cells evade T cell-mediated immunosurveillance via the interaction between programmed death-1 (PD-1) ligand 1 (PD-L1) on tumor cells and PD-1 on T cells. Strategies disrupting PD-1/PD-L1 have shown clinical benefits in various cancers. However, the limited response rate prompts us to investigate the molecular regulation of PD-L1. Here, we identify trafficking protein particle complex subunit 4 (TRAPPC4), a major player in vesicular trafficking, as a crucial PD-L1 regulator. TRAPPC4 interacts with PD-L1 in recycling endosomes, acting as a scaffold between PD-L1 and RAB11, and promoting RAB11-mediated recycling of PD-L1, thus replenishing its distribution on the tumor cell surface. TRAPPC4 depletion leads to a significant reduction of PD-L1 expression in vivo and in vitro. This reduction in PD-L1 facilitates T cell-mediated cytotoxicity. Overexpression of Trappc4 sensitizes tumor cells to checkpoint therapy in murine tumor models, suggesting TRAPPC4 as a therapeutic target to enhance anti-tumor immunity.
引用
收藏
相关论文
共 50 条
  • [31] Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents
    Assi, Hikmat H.
    Wong, Chihunt
    Tipton, Kimberly A.
    Mei, Li
    Wong, Ken
    Razo, Jennifer
    Chan, Chanty
    Howng, Bruce
    Sagert, Jason
    Krimm, Michael
    Diep, Linnea
    Jang, Andrew
    Nguyen, Margaret T.
    Lapuyade, Nicole
    Singson, Victoria
    Villanueva, Ruth
    Paidhungat, Madan
    Liu, Shouchun
    Rangan, Vangipuram
    Vasiljeva, Olga
    West, James W.
    Richardson, Jennifer H.
    Irving, Bryan
    Daniel, Dylan
    Belvin, Marcia
    Kavanaugh, W. Michael
    CANCER IMMUNOLOGY RESEARCH, 2021, 9 (12) : 1451 - 1464
  • [32] MYC regulates the antitumor immune response through CD47 and PD-L1
    Casey, Stephanie C.
    Tong, Ling
    Li, Yulin
    Do, Rachel
    Walz, Susanne
    Fitzgerald, Kelly N.
    Gouw, Arvin M.
    Baylot, Virginie
    Guetgemann, Ines
    Eilers, Martin
    Felsher, Dean W.
    SCIENCE, 2016, 352 (6282) : 227 - 231
  • [33] PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
    Bocanegra, Ana
    Blanco, Ester
    Fernandez-Hinojal, Gonzalo
    Arasanz, Hugo
    Chocarro, Luisa
    Zuazo, Miren
    Morente, Pilar
    Vera, Ruth
    Escors, David
    Kochan, Grazyna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (16) : 1 - 17
  • [34] Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
    Escors, David
    Bocanegra, Ana
    Chocarro, Luisa
    Blanco, Ester
    Pineiro-Hermida, Sergio
    Garnica, Maider
    Fernandez-Rubio, Leticia
    Vera, Ruth
    Arasanz, Hugo
    Kochan, Grazyna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (21)
  • [35] Peptide self-assembled nanomedicine induces antitumor immunity by blocking the PD-1/PD-L1 axis
    Huang, Tao
    Sun, Xianfu
    Meng, Xiaocao
    Chen, Mengdie
    Li, Yapeng
    Du, Shengnan
    Qi, Yingqiu
    Ge, Hong
    FRONTIERS IN MATERIALS, 2022, 9
  • [36] A Bis-Indole-Derived NR4A1 Antagonist Induces PD-L1 Degradation and Enhances Antitumor Immunity
    Karki, Keshav
    Wright, Gus A.
    Mohankumar, Kumaravel
    Jin, Un-Ho
    Zhang, Xing-Han
    Safe, Stephen
    CANCER RESEARCH, 2020, 80 (05) : 1011 - 1023
  • [37] Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma
    Wang, Yichen
    Zhang, Xuyao
    Xu, Caili
    Nan, Yanyang
    Fan, Jiajun
    Zeng, Xian
    Kwon, Byoung S.
    Ju, Dianwen
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [38] DUAL-SPECIFIC ANTIBODIES BLOCKING BOTH PD-L1 AND PD-L2 ENGAGEMENT OF PD-1 RESTORE ANTITUMOR IMMUNITY
    Couillault, Coline
    Srinivasamani, Anupallavi
    Hedge, Shweta
    Liu, Qinying
    Jaiswal, Ashwin
    Zha, Dongxing
    Curran, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A315 - A315
  • [39] The intracellular signalosome of PD-L1 in cancer cells
    David Escors
    María Gato-Cañas
    Miren Zuazo
    Hugo Arasanz
    María Jesus García-Granda
    Ruth Vera
    Grazyna Kochan
    Signal Transduction and Targeted Therapy, 3
  • [40] The intracellular signalosome of PD-L1 in cancer cells
    Escors, David
    Gato-Canas, Maria
    Zuazo, Miren
    Arasanz, Hugo
    Jesus Garcia-Granda, Maria
    Vera, Ruth
    Kochan, Grazyna
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2018, 3